Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

Abstract Background Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efficacy of combination treatment with osimer...

Full description

Bibliographic Details
Main Authors: Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, Kenichi Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Adverse event
Epidermal growth factor receptor
Maximum tolerated dose
Resistance mechanism
Synergistic effect
Online Access:https://doi.org/10.1186/s12885-022-10467-w

Internet

https://doi.org/10.1186/s12885-022-10467-w

Similar Items